[ { "@graph" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84", "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ], "http://www.nanopub.org/nschema#hasAssertion" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#assertion" } ], "http://www.nanopub.org/nschema#hasProvenance" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#provenance" } ], "http://www.nanopub.org/nschema#hasPublicationInfo" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#pubInfo" } ] } ], "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#Head" }, { "@graph" : [ { "@id" : "http://identifiers.org/drugbank/DB00334", "@type" : [ "https://w3id.org/biolink/vocab/Drug" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "Olanzapine" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Drug" } ] }, { "@id" : "http://purl.obolibrary.org/obo/DOID_1574", "@type" : [ "https://w3id.org/biolink/vocab/Disease" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "alcohol use disorder" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Disease" } ] }, { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#association", "@type" : [ "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ { "@id" : "http://purl.obolibrary.org/obo/DOID_1574" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ { "@id" : "https://w3id.org/biolink/vocab/treats" } ], "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ { "@id" : "http://identifiers.org/drugbank/DB00334" } ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "Olanzapine was FDA approved for the treatment of schizophrenia and bipolar disorder only. It is an atypical antagonist of D2 and D4 receptors which determines a decrease in craving for alcohol. The DRD4 gene of dopamine presents a VNTR polymorphism, with a number of repetitions that varies from 2 to 11 which allows for the division of individuals in two subgroups: those with a number of repetitions between 2 and 6, classified as DRD4 S and those with more than 7 repetitions, classified as DRD4 L. Association studies between this variation and AUD have showed that individuals who carry the L allele exhibit greater craving after alcohol intake,50. Another study has investigated the association olanzapine-DRD4 showing that olanzapine reduces craving to the L allele carriers only, while no benefits were observed in S allele carriers." } ], "https://w3id.org/biolink/vocab/aggregator_knowledge_source" : [ { "@id" : "https://w3id.org/biolink/infores/knowledge-collaboratory" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation" } ], "https://w3id.org/biolink/vocab/has_population_context" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#context" } ], "https://w3id.org/biolink/vocab/publications" : [ { "@id" : "http://www.ncbi.nlm.nih.gov/pubmed/29912214" } ], "https://w3id.org/biolink/vocab/relation" : [ { "@id" : "http://purl.obolibrary.org/obo/NCIT_C94303" } ] }, { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#context", "@type" : [ "https://w3id.org/biolink/vocab/Cohort" ], "http://www.w3.org/2000/01/rdf-schema#label" : [ { "@value" : "adults" } ], "https://w3id.org/biolink/vocab/category" : [ { "@id" : "https://w3id.org/biolink/vocab/Cohort" } ] } ], "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#assertion" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#assertion", "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-7641-6446" } ] } ], "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#provenance" }, { "@graph" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84", "http://www.w3.org/ns/prov#generatedAtTime" : [ { "@type" : "http://www.w3.org/2001/XMLSchema#dateTime", "@value" : "2022-09-16T11:54:35.529379" } ], "http://www.w3.org/ns/prov#wasAttributedTo" : [ { "@id" : "https://orcid.org/0000-0002-1501-1082" } ], "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ { "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY" } ] }, { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#sig", "http://purl.org/nanopub/x/hasAlgorithm" : [ { "@value" : "RSA" } ], "http://purl.org/nanopub/x/hasPublicKey" : [ { "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCR9fz0fKCdWOWC+pxhkQhEM/ppbdIYe5TLSdj+lJzSlv9mYBaPgrzVezSwwbmhlHBPDZa4/vHycU315BdmUGq+pXllp9+rWFfrb+kBJwhZjpG6BeyyXBsRFz4jmQVxl/ZYHilQTh/XalYzKkEAyTiEMPee4Kz61PaWOKH24CsnOQIDAQAB" } ], "http://purl.org/nanopub/x/hasSignature" : [ { "@value" : "EZH5DT4K3l3uk6H65DHWAFQwIG+q31cWFOWWvUTRFQEbfkP87pLflbnQY7oS7uK9Y2L1/1z7o1EAR8ztBHhZBiyhtO0V2nHq+BNRb4bTQw5R6rSh7tLcxWc0nWl4tfQKmTRJFa/E1ZlhMXlourWMY1+X7ekIYjn7T3WtuTCDpnQ=" } ], "http://purl.org/nanopub/x/hasSignatureTarget" : [ { "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84" } ] }, { "@id" : "https://w3id.org/biolink/vocab/", "http://purl.org/pav/version" : [ { "@value" : "2.3.0" } ] } ], "@id" : "http://purl.org/np/RAJ_wIH5Q8hc-PhR4wSLNcXLgaWO6Kp5wHrKZhkyOPn84#pubInfo" } ]